Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.
Authors
Elander, NAughton, K
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Campbell, F
Costello, E
Halloran, C
Mackey, J
Scarfe, A
Valle, Juan W
McDonald, A
Carter, R
Tebbutt, N
Goldstein, D
Shannon, J
Dervenis, C
Glimelius, B
Deakin, M
Charnley, R
Anthoney, A
Lerch, M
Mayerle, J
Oláh, A
Büchler, M
Greenhalf, W
Affiliation
Cancer Research U.K. Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, UKIssue Date
2018-04
Metadata
Show full item recordAbstract
Deoxycytidylate deaminase (DCTD) and ribonucleotide reductase subunit M1 (RRM1) are potential prognostic and predictive biomarkers for pyrimidine-based chemotherapy in pancreatic adenocarcinoma.Citation
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. 2018, 118(8): 1084-1088 Br J CancerJournal
British Journal of CancerDOI
10.1038/s41416-018-0005-1PubMed ID
29523831Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/s41416-018-0005-1
Scopus Count
Collections
Related articles
- Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
- Authors: Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T
- Issue date: 2013 Apr
- Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
- Authors: Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X, Liu X
- Issue date: 2013 Jan 1
- Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
- Authors: Kim R, Tan A, Lai KK, Jiang J, Wang Y, Rybicki LA, Liu X
- Issue date: 2011 Jul 15
- An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
- Authors: Fisher SB, Patel SH, Bagci P, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Maithel SK
- Issue date: 2013 Jan 15
- Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
- Authors: Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL
- Issue date: 2012 Sep